Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Sanofi is among the most undervalued stocks. 

Between December 8 and December 10, 2025, SNY faced a series of analyst rating adjustments that tempered investor sentiment. The Fly reported on Monday, December 8, 2025, that J.P. Morgan downgraded SNY from Overweight to Neutral, signaling a more cautious near-term outlook for the company.

The following day, Guggenheim lowered its rating from Buy to Neutral, marking a second downgrade in less than 48 hours. On Wednesday, December 10, 2025, HSBC trimmed its price target from EUR 102 to EUR 100 while maintaining its Buy rating, further contributing to market caution.

These analyst actions reflect reduced optimism about Sanofi (NASDAQ:SNY)’s near-term growth prospects and potential catalysts. While the downgrades occurred in close succession, the analysts’ published notes focused primarily on valuation considerations and limited near-term pipeline catalysts, rather than any confirmed regulatory setbacks.

Separately, market observers reported that U.S. regulators launched renewed safety scrutiny of approved infant RSV therapies, including SNY’s Beyfortus, following inquiries into safety data. This review is ongoing and does not constitute an official safety finding, but it highlights a level of regulatory attention that could influence investor sentiment.

Sanofi (NASDAQ:SNY) is a global healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions across pharmaceuticals, vaccines, and consumer healthcare.

While we acknowledge the risk and potential of SNY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SNY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Blue Chip Stocks to Buy Under $50 and11 Best Low Priced Dividend Stocks to Buy According to Analysts.

Disclosure: None.